@alliance-org
Part of the National Clinical Trials Network, the Alliance for Clinical Trials in Oncology is a leader in advancing cancer research, uniting more than 25,000 cancer specialists at 115 main institutions and 1,400 affiliates across the U.S. and Canada.
At #ASCOGI2026, Alliance investigators showed new ways to preserve organs in rectal cancer, how exercise may support GI cancer recovery, and new understanding biomarkers to guide more personalized treatments. More: https://bit.ly/Alliance-GI #ColorectalCancerAwarenessMonth
Dr. Anne Beaven of UNC Lineberger leads Alliance for Clinical Trials in Oncology A052101, a trial to see if older people with mantle cell lymphoma can receive fewer treatments of the targeted cancer medicine zanubrutinib while in remission. Learn more: https://bit.ly/Alliance-A052101
The results of NRG/Alliance LU005 in the Journal of Clinical Oncology show immunotherapy given during and after chemoradiation does not improve survival for patients with limited-stage, small-cell lung cancer. https://bit.ly/SCLC-Mar2026 American Society of Clinical Oncology NRGOnc
New trial! Drs. Thomas Hope of UCSF and Deaglan McHugh of Memorial Sloan Kettering Cancer Center lead Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer https://bit.ly/AllianceA032304
New trial! The Alliance has a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. Visit https://bit.ly/CLL-SLL to learn about Alliance A042302 led by Dr. Jennifer R. Brown of Dana-Farber Cancer Institute
Dr. Haeseong Park of Dana-Farber Cancer Institute leads Alliance A022102 studying mFOLFIRINOX vs mFOLFOX with or without immunotherapy for metastatic HER2 negative esophageal, gastroesophageal junction and gastric cancer. Learn more: https://bit.ly/Alliance-A022102 #ColorectalCancerAwarenessMonth
Trial Tuesday! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling Alliance for Clinical Trials in Oncology A032302, the ASPIRE trial to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. Learn more at http://bit.ly/AllianceA032302.
The Alliance has 10 active clinical trials focused on improving treatments for colorectal cancers and others aimed preventing the disease or catching it very early when symptoms are most easily and effectively treated. Learn more https://bit.ly/CRC-March #colorectalcancerawarenessmonth
Now enrolling! The phase III HOPE study (A222301) led by Anurag Singh, MD of Roswell Park Comprehensive Cancer Center is assessing if high-dose gabapentin reduces opioid use in patients with oral mucositis during chemoradiation for head and neck cancer. Learn more: https://bit.ly/Alliance-A222301
Now enrolling! Bhavana Konda, MD, MPH, of Ohio State leads Alliance for Clinical Trials in Oncology A092204 exploring if using two targeted medications can help slow tumor growth in people with advanced adrenocortical carcinoma, a rare cancer of the adrenal glands. https://bit.ly/A092204-Konda #NCI
With colorectal cancer, if one has an inherited gene change, other family members are at risk. Alliance A212101 will evaluate if family is more likely to get genetic testing to catch disease early if they hear about risks from a provider https://bit.ly/CRCGene-Testing #ColorectalCancerAwarenessMonth
A blood test could help doctors decide which patients with advanced colon cancer should receive NSAIDs along with chemotherapy after surgery, according to new study on Alliance data in JAMA Oncology. JAMA Oncology
https://bit.ly/JAMA-NSAID #ColorectalCancerAwarenessMonth
The Alliance is more than finding new and better ways to cure cancer; we also work to prevent it. The Alliance has three active trials focusing on lowering the chances of cancer developing in the first place. More at https://bit.ly/Prevent26
New Trial! Dr. Gabriel Brooks of Dartmouth Cancer leads the PAGODA trial (Alliance A232402CD) aimed to reduce unplanned treatment delays in people with gastrointestinal cancers. Learn more at https://bit.ly/PAGODA26. #ColorectalCancerAwarenessMonth
🚨 New research from Alliance A222001 by Dr. Bradley Stish at Mayo Clinic shows oxybutynin significantly reduces hot flashes in men undergoing hormone therapy for prostate cancer. Findings published in the Journal of Clinical Oncology. More at https://bit.ly/Stish-JCO
The Alliance will host a free webinar on March 16 showcasing key research from Alliance investigators presented at the ASH and SABCS meetings. The virtual event will highlight advances impacting treatments for breast cancer, multiple myeloma, and leukemia. https://bit.ly/AllianceMar16Webinar
The #ERASur trial is enrolling patients with #colorectalcancer that has spread beyond the liver. Patients who responded to initial chemo & have up to 4 treatable cancer sites are eligible to participate. Learn more: https://bit.ly/Alliance-A022101 #ColorectalCancerAwarenessMonth
Now enrolling! Angela Bradbury MD of Penn Medicine - Abramson Cancer Center leads
A232301CD seeing if digital chatbot intervention is as effective as standard remote genetic services in increasing counseling uptake among adolescent & young adult cancer patients https://bit.ly/AllianceA232301CD
The Alliance will host a free webinar on March 16 showcasing key research from Alliance investigators presented at the ASH and SABCS meetings. The virtual event will highlight advances impacting treatments for breast cancer, multiple myeloma, and leukemia. https://bit.ly/AllianceMar16Webinar
New publication alert! Results of Alliance A071401 in Nature Medicine show abemaciclib may slow growth of aggressive meningiomas with NF2 or CDK pathway mutations: 58% of high grade tumors didn’t progress at 6 months https://bit.ly/Brastianos bit.ly/A071401
New trial! Jennifer Ligibel MD of Dana-Farber Cancer Institute & Kathryn Schmitz PhD of UPMC Hillman Cancer Center lead Alliance A222302 studying the feasibility of a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. https://bit.ly/DEFEND-trial #NCTN
Trial Tuesday! Dr. Matt Galsky of Icahn Mount Sinai leads Alliance A032103/MODERN trial investigating if DNA released from tumor cells into the blood helps identify the best #immunotherapy treatment after surgery for #bladdercancer. More info: https://bit.ly/Alliance-A032103
BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. If your cancer returned after BCG, the Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer
Now recruiting! Dr. Bradley McGregor of the Dana-Farber Cancer Institute leads Alliance A032201 (STRIKE) to see if adding the tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCTN
RanaMcKay, MD, of UC San Diego Health leads Alliance for Clinical Trials in Oncology
A031801 (RadiCaL) testing if adding the new anti-cancer drug radium-223 dichloride to the usual chemo drug cabozantinib improves outcomes for advanced renal cell cancer. Learn more at http://bit.ly/AllianceA031801
New publication alert! Findings from the phase III AFT-38 PATINA trial published in the New England Journal of Medicine show that adding palbociclib to standard maintenance therapy show significant progression-free survival benefit in advanced breast cancer. bit.ly/26PATINA bit.ly/NEJM-PATINA
Trial Tuesday! Rana McKay, MD, of UC San Diego Health and Misha Beltran Dana-Farber Cancer Institute co-lead Alliance A032102/PREDICT evaluating if genetic testing helps determine the best treatment regimen for men with metastatic prostate cancer. Learn more at https://bit.ly/Alliance-A032102
Sara Tolaney of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012103 for early-stage breast cancer patients. This phase III trial compares continuing pembrolizumab vs monitoring after surgery. Learn more at https://bit.ly/Alliance-A012103
At #ASCOGI2026, Alliance investigators showed new ways to preserve organs in rectal cancer to how exercise may support GI cancer recovery, plus progress in understanding biomarkers to guide more personalized treatments. Learn more https://bit.ly/Alliance-GI
New trial! Dr. Thomas Hope of UCSF and Dr. Deaglan McHugh of Memorial Sloan Kettering Cancer Center lead Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer https://bit.ly/AllianceA032304